3 days popular7 days popular1 month popular3 months popular

Interferon And Ribavirin Inhibit Coronavirus Replication In Cell Culture

National Institutes of Health () scientists studying an emerging coronavirus have found that a combination of two licensed , and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These results suggest that the drug combination could be used to treat patients infected with the new coronavirus, but more research is needed to confirm this preliminary finding. The study appears in the journal Scientific Reports.

The new coronavirus, called nCoV, was first identified in Saudi Arabia in September 2012. As of April 16, 2013, the has reported 17 cases with 11 deaths, primarily in the Middle East. Although the case count is small, the new coronavirus has transmitted from human-to-human in situations where people – mainly family members – have had close contact with those infected.

Because of the high fatality rate, scientists at NIH’s National Institute of Allergy and Infectious Diseases () saw an urgent need to identify therapeutic options. In laboratory tests using cells from two species of monkey, the researchers found that either ribavirin or interferon-alpha 2b, drugs currently approved for hepatitis C therapy, inhibited nCoV from replicating when used individually. However, the required drug concentrations exceeded what is recommended for people. By combining the two antivirals, the scientists established an effective treatment dose at a drug level that is achievable in people. The plan to confirm these results in a recently developed monkey model of nCoV infection.*

Source

* http://www.niaid.nih.gov/news/newsreleases/2013/Pages/NovelCoronavirus.aspx
ARTICLES:
Falzarano et al. Inhibition of novel human coronavirus-EMC replication by a combination of interferon-alpha2b and ribavirin. Scientific Reports DOI: 10.1038/srep01686 (2013).
Munster et al. Novel Human Coronavirus Causes Pneumonia in a Macaque Model Resembling Human Disease. New England Journal of Medicine DOI: 10.1056/NEJMc1215691 (2013).
Vincent Munster, Ph.D., chief of the virus ecology unit in NIAID’s Laboratory of Virology, is leading the NIAID team investigating the new coronavirus.
NIH/National Institute of Allergy and Infectious Diseases